Zymeworks upgraded to Overweight on 2025 pipeline at JPMorgan

JPMorgan upgraded Zymeworks (ZYME) to Overweight from Neutral with a price target of $18, up from $12 following last week’s research and development day. The firm left the event more confident in the company’s oncology and autoimmune diseases pipeline. With partnered Ziihera “providing a solid support to the valuation, 2025 is the year investors should pay attention for Zymeworks, the analyst tells investors in a research note. The firm says the company could begin to see one or more of its “5×5” plan succeeding in the clinics.